PRN News Wire — January 28, 2021
Bright Path Labs has appointed Mr. Marc Fasteau as an independent director. Tony Quinones, CEO of BPL, stated, “We are extraordinarily honored and pleased that Mr. Fasteau has elected to join our board as an independent director.” Mr. Fasteau is a lawyer, former partner at New York investment bank Dillon Read and founder and former chairman of the American Strategic Insurance, property & casualty insurance group. Mr. Fasteau serves on the board of Oxford Performance Materials, a privately held advanced materials company that manufactures 3-D printed vertebrae, suture anchors, replacement eye sockets and other in-body bony structures. The material also has aerospace and industrial applications. He served on the professional staffs of the US Senate Majority Leader, the House Banking & Currency Committee and Joint Economic Committee. He also served as staff director and counsel to a Rockefeller Foundation Commission on US policy toward South Africa.
Mr. Fasteau has been involved in questions of international trade and industrial policy for 16 years and has been a member of the board of the Coalition for A Prosperous America since 2014. He serves on the Economic Advisory Committee of the Center for American Progress. Mr. Fasteau has written on international trade and industrial policy in the Financial Times Economist Forum, The Huffington Post, and Palladium magazine. He is writing a book on industrial policy for the United States.
He is a graduate of Harvard College and Harvard Law School where he was an editor of the Harvard Law Review.
About Bright Path Laboratories, Inc.
Bright Path Laboratories, Inc. is a commercial stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathlabs.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.